Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Antecedent Metabolic Health and Metformin (ANTHEM) Aging study: Rationale and study design for a randomized controlled trial

Santosh Kumari, View ORCID ProfileMatthew Bubak, Hayden M. Schoenberg, View ORCID ProfileArik Davidyan, Christian J. Elliehausen, Katrin G. Kuhn, Timothy M. VanWagoner, Rowan Karaman, Robert Hal Scofield, View ORCID ProfileBenjamin F. Miller, View ORCID ProfileAdam R. Konopka
doi: https://doi.org/10.1101/2021.10.20.21265196
Santosh Kumari
1Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, Madison, WI
2Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Bubak
3Aging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew Bubak
Hayden M. Schoenberg
1Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, Madison, WI
2Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI
B.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arik Davidyan
3Aging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Arik Davidyan
Christian J. Elliehausen
1Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, Madison, WI
2Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katrin G. Kuhn
4Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy M. VanWagoner
5Oklahoma Shared Clinical and Translational Resources, University of Oklahoma Health Sciences Center, Oklahoma City, OK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rowan Karaman
6Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Wisconsin-Madison, Madison, WI
7Division of Endocrinology, William S. Middleton Memorial Veterans Hospital, Madison, WI
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Hal Scofield
8Department of Veterans Affairs Medical Center, Oklahoma City, OK
9Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
10Endocrinology, Diabetes and Metabolism Section, Department of Medicine, University of Oklahoma Health Sceinces Center, Oklahoma City, OK
11Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin F. Miller
3Aging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
11Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
12Oklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Benjamin F. Miller
Adam R. Konopka
1Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, Madison, WI
2Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adam R. Konopka
  • For correspondence: akonopka{at}medicine.wisc.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The antidiabetic medication metformin has been proposed to be the first drug tested to target aging and extend healthspan in humans. While there is extensive epidemiological support for the health benefits of metformin in patient populations, it is not clear if these protective effects apply to those free of age-related disease. Our previous data in older adults without diabetes suggest a dichotomous change in insulin sensitivity and skeletal muscle mitochondrial adaptations after metformin treatment when co-prescribed with exercise. Those who entered the study as insulin sensitive had no change to detrimental effects while those who were insulin resistant had positive changes. The objective of this clinical trial is to determine if 1) antecedent metabolic health and 2) skeletal muscle mitochondrial remodeling and function mediate the positive or detrimental effects of metformin monotherapy, independent of exercise, on the metabolism and biology of aging. In a randomized, double blind clinical trial, adults free of chronic disease (n=148, 40-75 years old) are stratified as either insulin sensitive or insulin resistant based on HOMA-IR (≤2.2 or ≥2.5) and take 1500 mg/day of metformin or placebo for 12 weeks. Hyperinsulinemic-euglycemic clamps and skeletal muscle biopsies are performed before and after 12 weeks to assess primary outcomes of peripheral insulin sensitivity and mitochondrial remodeling and function. Findings from this trial will identify clinical characteristics and cellular mechanisms involved in modulating the effectiveness of metformin treatment to target aging that could inform larger phase 3 clinical trials aimed at testing aging as an indication for metformin.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04264897

Funding Statement

This work is supported by National Institute of Aging Grant R01 AG064951 (BFM), the Clinical and Translational Science Award (CTSA) program through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR002373 (UWM), the Oklahoma Shared Clinical and Translational Resources, grant U54GM104938 (OUHSC), and Dexcom, Inc (ARK). The work at UWM is supported using facilities and resources from the William S. Middleton Memorial Veterans Hospital. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the Department of Veterans Affairs, or the United States Government.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The University of Oklahoma Health Sciences Center serves as the single IRB of record and approved all study procedures.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study will be available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted October 24, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Antecedent Metabolic Health and Metformin (ANTHEM) Aging study: Rationale and study design for a randomized controlled trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antecedent Metabolic Health and Metformin (ANTHEM) Aging study: Rationale and study design for a randomized controlled trial
Santosh Kumari, Matthew Bubak, Hayden M. Schoenberg, Arik Davidyan, Christian J. Elliehausen, Katrin G. Kuhn, Timothy M. VanWagoner, Rowan Karaman, Robert Hal Scofield, Benjamin F. Miller, Adam R. Konopka
medRxiv 2021.10.20.21265196; doi: https://doi.org/10.1101/2021.10.20.21265196
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Antecedent Metabolic Health and Metformin (ANTHEM) Aging study: Rationale and study design for a randomized controlled trial
Santosh Kumari, Matthew Bubak, Hayden M. Schoenberg, Arik Davidyan, Christian J. Elliehausen, Katrin G. Kuhn, Timothy M. VanWagoner, Rowan Karaman, Robert Hal Scofield, Benjamin F. Miller, Adam R. Konopka
medRxiv 2021.10.20.21265196; doi: https://doi.org/10.1101/2021.10.20.21265196

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Geriatric Medicine
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)